Citation Impact
Citing Papers
Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C
2007
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria
2012
Safety of Drotrecogin Alfa (Activated) in Surgical Patients with Severe Sepsis
2004
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
2003
Early and individualized goal-directed therapy for trauma-induced coagulopathy
2012
Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective
2006
Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis
2010 Standout
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
Immunomodulation in the critically ill
2009
Acute Coagulopathy of Trauma: Hypoperfusion Induces Systemic Anticoagulation and Hyperfibrinolysis
2008
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
2020 Standout
Acute kidney injury
2012 Standout
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Intracerebral haemorrhage
2009 Standout
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
2004 Standout
Damage control in the injured patient
2011
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Promoting Global Research Excellence in Severe Sepsis (PROGRESS): Lessons from an International Sepsis Registry
2009
PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake
2018 StandoutNobel
Drotrecogin Alfa (Activated) in Adults with Septic Shock
2012 Standout
Management of Sepsis
2006
Host–pathogen interactions in sepsis
2007
Recombinant factor VIIa in trauma patients with the ‘triad of death’
2011
Safety of Recombinant Activated Factor VII in Randomized Clinical Trials
2010
Trauma-associated bleeding
2016
Sepsis: pathophysiology and clinical management
2016
Sepsis and Septic Shock: A History
2009
Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo
2012 Standout
Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis
2007
Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy
2016
Melioidosis
2012 Standout
Atherosclerosis: current pathogenesis and therapeutic options
2011 Standout
Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors
2009
Management of bleeding following major trauma: a European guideline
2007
Sepsis: a roadmap for future research
2015
Inflammation and coagulation
2010
Severe Sepsis and Septic Shock
2013 Standout
Novel strategies for the treatment of sepsis
2003
Transfusion Interventions in Critical Bleeding Requiring Massive Transfusion: A Systematic Review
2015
Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice
2017 Standout
The proinflammatory mediator Platelet Activating Factor is an effective substrate for human group X secreted phospholipase A2
2006
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
2008 Standout
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Complement: a key system for immune surveillance and homeostasis
2010 Standout
Early prediction of acute traumatic coagulopathy
2011
Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival
2009
The enigma of sepsis
2003
Acute kidney injury
2019 Standout
Sepsis and septic shock
2018 Standout
Rekombinanter Faktor VIIa in der Hämorrhagiebehandlung des Schwerstverletzten
2012
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
2003
Massive Transfusion Protocols: The Role of Aggressive Resuscitation Versus Product Ratio in Mortality Reduction
2009
Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?
2005
Hydrocortisone Therapy for Patients with Septic Shock
2008 Standout
Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
2008 Standout
Risks and Benefits of Activated Protein C Treatment for Severe Sepsis
2002
Host innate immune responses to sepsis
2013
Brazilian Sepsis Epidemiological Study (BASES study)
2004
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
Development and validation of a prehospital prediction model for acute traumatic coagulopathy
2016
Damage control resuscitation in patients with severe traumatic hemorrhage
2016
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
Recombinant factor VIIA is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients
2011
„Hämoglobinorientierter und gerinnungsfaktorbasierter Algorithmus“
2015
Recombinant Activated Factor VII Safety in Trauma Patients: Results From the CONTROL Trial
2011
Trauma, Transfusions, and Use of Recombinant Factor VIIa: A Multicenter Case Registry Report of 380 Patients from the Western Trauma Association
2010
The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent
2008
The Pathophysiology and Treatment of Sepsis
2003 Standout
Coagulation and sepsis
2016
Emerging drugs for the treatment of sepsis
2016
Clotting Factor Deficiency in Early Trauma-Associated Coagulopathy
2011
Massive transfusion and nonsurgical hemostatic agents
2008
Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding
2016
Current treatment of severe sepsis
2006
The immunopathology of sepsis and potential therapeutic targets
2017 Standout
The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care
2018 Standout
Results of the CONTROL Trial: Efficacy and Safety of Recombinant Activated Factor VII in the Management of Refractory Traumatic Hemorrhage
2010
Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies
2014
Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms
2008
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
2009 Standout
Coagulopathy and blood component transfusion in trauma
2005
Variation in critical care services across North America and Western Europe*
2008
Cardiovascular management of septic shock
2003
Incidence and Outcomes of Acute Lung Injury
2005 Standout
Prevalence and Significance of Coagulation Abnormalities in Community-Acquired Pneumonia
2009
The Epidemiology of Sepsis in the United States from 1979 through 2000
2003 Standout
Prevention and Treatment of Major Blood Loss
2007
The dark side of C5a in sepsis
2004
Extracellular histones are major mediators of death in sepsis
2009 Standout
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*
2003
Effects of recombinant activated factor VIIa on abdominal trauma patients
2013
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Management of bleeding and coagulopathy following major trauma: an updated European guideline
2013
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
2016 Standout
Management of bleeding following major trauma: an updated European guideline
2010
Blood Transfusion is an Independent Predictor of Mortality after Blunt Trauma
2007
Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy
2005
A retrospective case control study of recombinant factor VIIa in patients with intracranial haemorrhage caused by trauma
2011
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
Low-dose recombinant factor VIIa for reversing coagulopathy in patients with isolated traumatic brain injury
2014
The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome
2003
Part 9: Post–Cardiac Arrest Care
2010 Standout
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial
2011 Standout
The cytoprotective protein C pathway
2006
The interactions between inflammation and coagulation
2005
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
2005 Standout
Protocolized Care for Early Septic Shock (ProCESS) statistical analysis plan.
2013
A Randomized Trial of Protocol-Based Care for Early Septic Shock
2014 Standout
The Effects of Protocolized Use of Recombinant Factor VIIa Within a Massive Transfusion Protocol in a Civilian Level I Trauma Center
2011
Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure
2011 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012
2014
The ADRENAL study protocol: ADjunctive corticosteroid tREatment iN criticAlly ilL patients with septic shock
2013
Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications
2011
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 Standout
Circulating Platelet-Activating Factor Is Primarily Cleared by Transport, Not Intravascular Hydrolysis by Lipoprotein-Associated Phospholipase A 2 / PAF Acetylhydrolase
2010
Risk of Thromboembolic Events in Controlled Trials of rFVIIa in Spontaneous Intracerebral Hemorrhage
2008
Local and systemic hemostatics in trauma: a review.
2008
Developing a New Definition and Assessing New Clinical Criteria for Septic Shock
2016 Standout
Part 14: Pediatric Advanced Life Support
2010 Standout
Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle
2015 StandoutNobel
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
2013
Guideline on antiplatelet and anticoagulation management in cardiac surgery
2008
Damage Control Resuscitation
2014
The enigma of sepsis
2003
Works of Brian Warren being referenced
Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
2006
Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
2006
Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-Blind Clinical Trials
2005
Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hocanalysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
2007
The treatment of bleeding is to stop the bleeding! Treatment of trauma‐related hemorrhage
2009
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*
2004
High-Dose Antithrombin III in Severe Sepsis
2001
High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*
2006
Prolonged Prothrombin Time After Recombinant Activated Factor VII Therapy in Critically Bleeding Trauma Patients Is Associated With Adverse Outcomes
2010
Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study
2006
DECREASED TRANSFUSION UTILIZATION AND IMPROVED OUTCOME ASSOCIATED WITH THE USE OF RECOMBINANT FACTOR VIIA AS AN ADJUNT IN TRAUMA
2004